The Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) drugs in development market research report provides comprehensive information on the therapeutics under development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) and features dormant and discontinued products.
GlobalData tracks 18 drugs in development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) by 15 companies/universities/institutes. The top development phase for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) is preclinical with nine drugs in that stage. The Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) pipeline has 15 drugs in development by companies and three by universities/ institutes. Some of the companies in the Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) pipeline products market are: Wuhan Neurophth Biological Technology, GenSight Biologics and Biovista.
The key targets in the Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) pipeline products market include NADH Ubiquinone Oxidoreductase Chain 4, NADH Ubiquinone Oxidoreductase Chain 1, and Peptidyl Prolyl Cis-Trans Isomerase F Mitochondrial.
The key mechanisms of action in the Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) pipeline product include NADH Ubiquinone Oxidoreductase Chain 4 Activator with three drugs in Filing rejected/Withdrawn. The Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) pipeline products include six routes of administration with the top ROA being Intravitreal and five key molecule types in the Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) pipeline products market including Small Molecule, and Gene Therapy.
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) overview
Leber’s hereditary optic neuropathy (LHON) is an inherited form of vision loss. This condition usually begins in a person’s teens or twenties; rare cases may appear in early childhood or later in adulthood. Males are affected much more often than females. Symptoms include eye pain or discomfort, numbness, tingling, and clouding of vision. Predisposing factors include age, tobacco smoking, alcohol, cancer-treating drugs, stress related chemicals, some antibiotics, and cyanogens.
For a complete picture of Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
